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Plasma derived medicines (PDM) including immunoglobulins, clotting factors and albumin are life saving medicines
which due to their high costs are inaccessible for many patients living in developing countries. By contrary
substantial volume of plasma as raw materials for production of these medicines are discarded worldwide. Good
quality recovered plasma, as a result of separation of donated blood into its components, could be used for
production of PDM. In 2011 Iranian donors donated about 2 million units of blood. A shift from administration of
whole blood to components therapy has resulted in the generation of over 250,000 liters of surplus of recovered
plasma. This created a good opportunity for Iran’s health care system to use this plasma for production of PDM.
Therefore Iran national transfusion service has started a contract fractionation program for converting recovered
plasma into PDM. This program not only provided essential PDM for Iran pharmaceutical market but also has
created a direct saving of about 8.5 million Euros in 2011 for national health sector. In addition this program has
drastically contributed to improvement of overall quality of working procedures and services provided by Iran
national blood transfusion organization.
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Although blood as a very precious human resource has
been used for direct transfusion for centuries it has re-
cently become increasingly important to separate the
manufacturing aspect of blood as a source of pharma-
ceutical “raw material”. The process of separating blood
into its components will result to plasma as a rich
source of human proteins for further manufacturing of
plasma derived medicines (PDM). Fractionation of
plasma could provide a wide range of medicines essen-
tial for management of patients with bleeding and im-
munological disorders. Coagulating factors including
factor VIII (FVIII), factor IX (FIX), von willebrand factor,
fibrinogen, fibrin sealants, prothrombin complex con-
centrate, albumin and immunoglobulins (IG) are among
the most used PDM around the world. Some of these
medicines including coagulation factors concentrates
and IG are on the WHO Model List of Essential Medi-
cine emphasizing their clinical importance. PrimaryCorrespondence: majidcheraghali@gmail.com
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reproduction in any medium, provided the orimmune deficiencies (PID) and bleeding disorders such
as haemophilia are among the most important disease
require PDM for their management. The majority of
patients with haemophilia or PID are currently not re-
ceiving adequate treatment, and the numbers of these
patients being diagnosed are increasing.
Global need for PDM have been increasing almost
geometrically over the last decade and based on evi-
dences for new indications of this medicines it seems
that administration of PDM will increase for years to
come [1]. Despite introduction of biotechnology for pro-
duction of some of these medicines including clotting
factors VIII and IX availability of others such as normal
and hyperimmune IG and even albumin is limited only
by the availability of plasma as their raw material for
fractionation. It is estimated that every year about 30
million liters of plasma fractionated worldwide [2]. How-
ever, there are considerable discrepancies among coun-
tries in production and fractionation capacities for
human plasma. Currently most plasma collection and
fractionation capacity are located in North America,
Europe and south East Asia. Although in some countries
fractionation facility may rely on recovered plasmatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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receive plasma produced through plasmapheresis from
remunerated donors. Currently about 75% of plasma
used for fractionation produced by plasmapheresis. Des-
pite good availability of PDM in high resource countries
many patients living in low resource countries in Africa,
South and Central America, and Asia do not have timely
access to PDM [2,3].
High costs and low availability of PDM in middle and
low income economies resulted to under treatment of
patients living in these countries. Based on data pre-
sented by patient oriented organizations [4,5] the major-
ity of patients with clotting disorders, immune
deficiencies, and autoimmune disorders living in middle
and lower income economies do not have adequate ac-
cess to PDM. Therefore availability of additional plasma
for fractionation could be used to generate essential
PDM and even national self sufficiency in plasma pro-
ducts can be achieved by reducing wastage of recovered
plasma. According to the number of donated blood
worldwide an estimated 21.6 million liters of plasma
could be recovered from these donations. Based on
number of plasma bags transfused for clinical use, it is
estimated that at least 9.3 million liters of plasma are
discarded annually [6,7].
Local fractionation of plasma and contract fraction-
ation are two main options for using recovered plasma
as an Active Pharmaceutical Ingredient (API) for pro-
duction of PDM. Although both options will provide
means to improve quality of the transfusion system and
availability of PDM, local fractionation requires substan-
tial investment of time and money due to the very high
level of complexity of the plasma fractionation technol-
ogy and regulatory issues [8]. However, in both cases
availability of sufficient volume of plasma with accept-
able quality is a pre requisite for starting any activity on
fractionation of plasma. Unlike small molecule medi-
cines cost related to the raw materials for producing
PDM is the costliest part of the manufacturing proced-
ure. Plasma represents approximately 30–40% of the
cost of PDM [3]. Therefore any program intended to use
produced plasma could create substantial saving on be-
half of both national health service and patients. Coun-
tries which are able to produce plasma meeting quality
requirements for fractionation in sufficient volume (e.g.
from 10,000 to 30,000 liters) could establish a contract
fractionation program. Contract fractionation program
could provide a safe, secure and reliable supply of life-
saving PDM [8].
In addition to other advantages of contract fraction-
ation including tangible effects on quality of the blood
transfusion system and transfusion safety [9] it could
also serve as a good educational tool to build-up know-
ledge in the field before possible establishment of adomestic fractionation plant. Involvement of national
regulatory authority in contract fractionation project
would provide training field for local regulators to be
prepared for regulation of possible future domestic frac-
tionation facility.
However, success of any contract fractionation pro-
gram requires some essential pre requisites. A contract
fractionation agreement is a mutual activity that should
follow transparent and well-established agreements be-
tween plasma supplier and fractionator company.
Among other items volume and quality of plasma and
costs of fractionation are of the utmost importance.
Range of the products should be well-balanced based on
the country’s needs to PDM. Therefore, successful con-
tract fractionation programs could serve as a ramp-up
phase for establishment of local fractionation facility,
wherever feasible. That is why some developing coun-
tries with contract fractionation program have estab-
lished a long term plan for establishment of local
fractionation facility in their national policy for plasma.
However, due to practical difficulties regarding transfer
of plasma fractionation technology this major move
should be done only after a very careful assessment and
feasibility study based on presence of strong government
endorsement and in particular the volume of plasma
available. Since building a high tech GMP-compliant
plasma fractionation facility require considerable invest-
ment, contract fractionation activity could be considered
a valuable training activity for national staff to build a
team of skilled manpower.
Despite presence of considerable number of fraction-
ation facilities worldwide, there are only few countries
which have reached full self sufficiently for providing
PDM for their own market and most of the countries
have to rely on importation of PDM in order to response
to the patients’ need. Although more than 50% of global
fractionators are located in the Asia-Pacific region, many
fractionation plants in this region have small capacity or
produce short range of the products. The total plasma
volume fractionated in 2010 in this region is close to 6.4
million liters. The coverage of local needs by products
prepared from domestic Japanese plasma is about 25%
for factor VIII, 58% for albumin and 95% for IG in 2010.
The volume of plasma fractionated in Korea is about
870,000 liters. China with over 25 plasma fractionation
in 2010 fractionated about 3.4 million liters of plasma
which has been collected exclusively by plasmapheresis
from remunerated donors [2].
Finding
Iran contract fractionation program
Iran, a country with a population of over 74 millions,
has one of the largest pharmaceutical market in the
Middle East. Blood transfusion In Iran is an integral part
Figure 1 Volume of plasma (liters) shipped by IBRF for
fractionation, 2005–2011.
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mentary law, Iran Blood Transfusion Organization
(IBTO) was established in order to centralize all blood
transfusion activities from donor recruitment to produc-
tion of blood components in one organization. IBTO is
a public and non-profit organization that relies on the
government of Iran for its budget and delivers all its
basic services including blood components free of charge
both to the public and private hospitals. Self sufficiently
of country for blood and blood components has always
been the main objective of IBTO. Since 2007 Iran has
reached to 100% voluntary donation and IBTO collects
blood only from non remunerated voluntary blood
donors. In 2011 Iranian donors donated about 2 million
units of blood to IBTO. In Iran in addition to the
screening of the donors through interviewing of the
donors all donated bloods undergo lab testing for pos-
sible presence of important and known blood borne dis-
eases including hepatitis B virus (HBV), hepatitis c virus
(HCV), human immunodeficiency virus (HIV) and syph-
ilis. Percent of confirmed HBsAg positive samples in
blood donated by Iranian donors has drastically
decreased from 0.8% in 2002 to 0.25% in 2010. Preva-
lence of confirmed HCV positive results has also
decreased from 0.18% in 2002 to 0.07% in 2010. Despite
increasing prevalence of HIV in general population
IBTO succeeded to reduce confirmed positive HIV sam-
ples in donated bloods to 0.004 in 2010 [10].
In recent decade administration of whole blood in
health centers of Iran has drastically declined and there-
fore majority of donated blood (>95%) are now con-
verted to blood components including packed red blood
cells, platelets and plasma. A shift from administration
of whole blood to component therapy has resulted in
the generation of surplus of recovered plasma from
donated blood. This created a good opportunity for
Iran's health care system to use this plasma for produc-
tion of PDM. In the other hand due to the improvement
of standards of care, consumption of PDM in Iran shows
a steady rise causing a significant burden on limited
resources available in national health sector [9].
Based on annual number of whole blood donation,
IBTO is able to produce about 250,000 liters of surplus
plasma annually. Therefore in order to use this plasma
for improving availability and affordability of PDM and
due to lack of any national fractionation facility, since
2005 IBTO and its sister company Iran Blood Research
and Fractionation Co. (IBRF) initiated a contract frac-
tionation program. Although improving the blood safety
profile of the country through improving quality assur-
ance system has been one of the main objectives of this
project, the program has also significantly improved
availability of PDM in the country [9]. IBTO has started
contract fractionation program with about 40,000 litersof plasma. However, the volume of plasma shipped for
fractionation has drastically increased in next years and
reached to over 130,000 liters in 2011 (Figure 1). Al-
though several countries both with developed and devel-
oping countries using contract fractionation as a means
for providing PDM, few countries have reported eco-
nomical impacts of their programs [11,12].
Cost effectiveness evaluation
Obviously the medicines produced from this volume of
plasma plays a critical role in providing essential PDM
to Iranian patients. Plasma is a very valuable raw mater-
ial and should be converted to as much medicines as
practically possible. It has been reported that the cost of
one liter of plasma, meeting the requirements for frac-
tionation, is worth between 60–100 Euros [13]. There-
fore, the production yield was one of the major
considerations for IBRF when negotiating with fractiona-
tors. In addition in order to reach to a balanced product
mix and optimize the cost effectiveness of plasma frac-
tionation it is necessary that each liter of plasma should
be used to produce as many PDM as possible. The aver-
age yields of products produced from one liter of recov-
ered Iranian plasma in contract fractionation program
are shown in Table 1. Average annual consumption of
PDM in Iran market and share of PDM obtained
through national contract fractionation program are also
depicted in Table 2. In 2011 Iran national contract
manufacturing project succeeded to produce 100% of
IVIG and FIX, 15% of FVIII and 40% of albumin con-
sumed in Iran’s market.
In contrary to blood and blood components which are
currently provided by IBTO free of charge for all Iranian
patients, PDM in Iran are regarded as medicines and
should be paid for. Except for antihemophilic factors
VIII and IX which are highly subsidized by the govern-
ment and are free of charge for hemophilia patients, cost
of IG and albumin should be borne by either insurance
companies or patient. IBTO and IBRF are non-profit





PDM, Plasma derived medicines; IVIG, Intravenous immunoglobulin; FIX, Factor
IX; FVIII, Factor VIII; IU, International unit.
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costs for contract fractionation including costs for
plasma preparation from donated bloods, its transporta-
tion and fractionation costs through products provided.
As expected, the price of PDM prepared by this program
is still notably lower than those of commercially avail-
able in the market (Table 3).
Despite strong support of the activity by governmental
officials especially Iran Ministry of Health, Iran contract
fractionation program does not receive any financial
support from the government and operates based on
cost recovery approach. Therefore average prices of
PDM produced through the national fractionation activ-
ity consists of contract fractionation costs, overhead and
administration costs, operational costs and costs for run-
ning and expanding the program (e.g. construction of
cold warehouses, procuring equipments, refrigerated
trucks). IBRF has recently constructed a new 50,000
liters capacity cold warehouse devoted to the program.
Based on data presented in Table 3 PDM produced
through plasma fractionation activity is substantially less
expensive compared to the commercially available medi-
cines in the Iran market. This obviously created a direct
savings for Iran public health budget as explained in
Table 4. This program in 2011 has created about 8.5
Million Euros direct saving for Iran national health care
system.
However, in addition to substantial direct effect of this
project on saving of resources allocated for importation
of PDM, indirect influence of the IBTO project on redu-
cing costs of imported commercial medicines is worth
mentioning. Availability of medicines produced from
Iranian plasma in the market has inevitably forced the
importers to offer more reasonable prices for their pro-
ducts in order to hold their shares in Iran’s market. InTable 2 Annual average consumption of PDM in Iran and
share of IBTO contact fractionation program in the
market (2011)
Medicine Average annual consumption % of Market share
IVIG 700 kg 100
FVIII 120 MIU 15
FIX 15 MIU 100
Albumin 8,500 Kg 40
PDM, Plasma derived medicines; IVIG, Intravenous immunoglobulin; FIX, Factor
IX; FVIII, Factor VIII; MIU, Million international unit.fact, the presence of the products produced from con-
tract fractionation in the market, through improving
bargaining power of the national authorities on commer-
cial products, has contributed greatly to maintain a
downward pressure on the price of the commercially
available PDM in Iran’s market [12].
Discussion
Although treatment of patients such as hemophilia and
PID patients with PDM is a life saving intervention, in
developing countries mainly due to limited resources
available in their national health sector, most of these
patients are not diagnosed or properly treated. Therefore
use of PDM in these countries is much lower than the
actual needs of patients [4,5]. Despite moderate increase
in demand for clotting factors and albumin in recent
years due to improved patient care and new clinical indi-
cation demand for IG therapy has greatly increased and
is now the driver for plasma collection industry [1].
By improving standards of practice in transfusion
medicine many countries even in developing countries
turned to components therapy instead of administration
of whole blood. Therefore as a consequence, millions of
additional plasma units could be generated which unfor-
tunately under current conditions are discarded. Wast-
age of plasma in these countries is not only could be
considered as a human tragedy but also is an economic
misfortune for their heath sector. Based on number of
donated blood globally it is estimated that every year at
least 9 million liters of recovered plasma discarded
worldwide. Therefore based on current prices for one
liter of plasma such wasted plasma has a market value of
about 650–900 million USD. Use of this volume of
plasma theoretically could result in about 1.4 billion
International Unit (IU) of FVIII. Based on annual use of
20,000 IU per patient this quantity of FVIII would allow
an additional 70,000 children with haemophilia A to be
treated each year. In addition, the same volume of
plasma can generate an additional 2.3 billion IU of FIX
necessary for treatment of an additional 57,500 haemo-
philia B children each year, assuming an annual con-
sumption of 40,000 IU/year/patient. More importantly
the same volume of recovered plasma could produce at
least 37 tons of IG. This quantity would be used to man-
age hundred thousand of PID patients. Finally, 230 tons
of albumin calculated on a mean recovery of 25 g/L,
could be produced from this volume of plasma. This
quantity would cover the needs of billion inhabitants
based on a consumption of 200 kg/million population. It
should also be kept in mind that plasma can be fractio-
nated to yield other PDM as well.
Therefore it is both ethical and economically feasible
for these countries to take measures to preserve and use
this plasma as API for production of PDM. Recovering
Table 3 Differences between average prices of PDM
produced through the contract fractionation program
compared with market average for imported PDM (2010)










PDM, Plasma derived medicines; IVIG, Intravenous immunoglobulin; FIX, Factor
IX; FVIII, Factor VIII; IU, International unit.
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would meet a substantial unmet health need. Addition-
ally such program will eventually improve national cap-
ability to provide all blood components of higher quality
and safety through upgrading blood collecting facilities
to the status of pharmaceutical manufacturers with ac-
ceptable GMP [9]. Currently in developing countries
much of the plasma generated as a side product of com-
ponent preparation due to its low quality and absence of
appropriate and standard freezing or storage capacity is
unusable for fractionation and therefore discarded. This
could not only be considered as wastage of valuable
resources but also may create environmental contamin-
ation. Obviously improving GMP in blood establish-
ments in these countries will conserve such plasma.
Contract fractionation of locally produced plasma
could substantially improve affordability of PDM espe-
cially in developing countries. In addition to saving on
the budget a contract fractionation program could also
protect the country from product shortages. In majority
of cases the contract fractionation program will provide
a reliable and affordable supply of PDM. However, it
should be mentioned that contact fractionation could at-
tract hostility from importers of PDM and the program
can be exposed to competition from temporarily low
prices for PDM in national market as result of “dump-
ing” by the importers. Therefore, contract fractionation
programs should be considered as a long term activity
and should not be reconsidered based on short term
fluctuation of PDM prices in the market.Table 4 Annual direct saving as a result of producing PDM th
importing such medicines (2011)





PDM, Plasma derived medicines; IVIG, Intravenous immunoglobulin; FIX, Factor IX; FConclusion
According to the WHO Secretariat Report in 2010 “a
large percentage of the plasma collected in developing
countries is categorized as waste material and destroyed.
This wastage occurs because appropriate technology,
regulatory controls, quality systems and good manufac-
turing practices are all lacking, thereby rendering the
plasma unsuitable for conversion into fractionated medi-
cinal” [7]. Therefore by improving quality of working
procedures a national blood service that separate plasma
from donated blood could supply it to a fractionator in
exchange of PDM in a plasma contract fractionation
program or, when justified, local production. In addition,
contract manufacturing programs could be considered
as a means to improve the transfusion system and en-
sure the availability of safe blood products. In order to
be able to use recovered plasma as API each unit of
recovered plasma should meet quality and safety
requirements. This is a fundamental pre-requisite to any
fractionation program.
It is obvious that successful fractionation programs re-
quire commitment and investment to establish, both on
the part of the blood collection service and the contract
fractionator. In any cases success of contract fraction-
ation activity requires strong and reliable governmental
commitment, effective framework, balanced products
basket and long term planning.
In order to be viable any contract fractionator program
needs to recover the establishment costs. Well planned
contract fractionation programs which rely on large
enough volume of plasma is a cost effective approach.
Iran, as a country faced with increasing demand for
PDM relies on its centralized blood transfusion system
for producing plasma for fractionation and has success-
fully implemented this approach in past years to im-
prove availability and affordability of these medicines.
Iran contract fractionation program has enjoyed strong
government commitment and support which should be
considered as one the main success elements of this pro-
gram. Iran experience has shown that contract plasma
fractionation through direct and indirect effects on price
of PDM could substantially improve availability and af-
fordability of such medicines in national health market.
In conclusion it is obvious that there is a need forrough contract fractionation program compared with
onsumption Annual saving (€)
50 kg 6,175,000
00 kg 1,360,000 (based on 40% market share)
5 MIU 600,000
0 MIU 420,000 (based on 15% market share)
VIII, Factor VIII; MIU, Million international unit.
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PDM and enhanced regulatory capacity in developing
countries to make the best use of recovered plasma.
Therefore, contract fractionation projects for the pro-
duction of PDM remain a practical approach to respond
to the needs of patients to PDM.
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